Does ischemic preconditioning occur in patients?  by Kloner, Robert A. & Yellon, Derek
III the history of attempts to rcducc myocardial infarct size, 
only a few therapies have stood the test of time. One is early 
reperfusion, which in both animal models and humans has 
been shown lo reduce myocardial infarct size, improve cardiac 
funclion and increase survival. Results with pharmacologic 
therapies, such as calcium channel blocking agents, beta- 
adrencrgic blocking agents, oxygen radical scavenging agents 
and neutrophil inhibitors have been variable. The ncwcst 
tcchniquc for reducing the size of experimental myocardial 
infarction is ischcmic preconditioning. The observation in fhe 
early I9XOs that brief repetitive COK~llil~ occlusions wcrc not 
associated with a progrcssivc loss in adcnosinc triphosphals 
levels (l,2) suggested that after an initial cpisodo of ischcmia a 
protective mechanism was preventing further degradation in 
high energy phosphates. Murry and et al. (3) observed that 
dogs subjected to 40 min of left circumflex coronary artery 
occlusion developed an average infarct size that was 20% of 
the ischemic area at risk; however, in dogs subjected to four 
S-min circumflex coronary occlusions, each separated by 5 min 
of reperfusion and then to the longer test occlusion of 40 min, 
average infarct size was only 7% of the ischemic area at risk. 
Thus, the brief periods of ischemia and reperfusion appeared 
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to precondition the heart, making it more resistant to a 
subsequent longer period of ischemia. Murry et al. (3.4) 
initially defined precondilionings as “a rapid, adaptive re- 
sponse to a brief ischcmic insult, which slowed the rate of ccl1 
death during a subsequent, prolonged period of ischemia.” 
Since their initial observation in dogs, similar findings have 
been observed in numerous research laboratories and in a wide 
range of spccics, including nol only dogs (S), but rabbits (0,7), 
rats (8,‘)) and pigs (!!I). It has truly been amazing to obscrvc so 
many laboratories showing the potential of preconditioning to 
reduce myocardial infarct size. Ahhough the initial definition 
of preconditioning refcrrcd to lhis limitation of infarct size, 
some invcsligators (I I, 12) have cxlcndcd the term to include 
limihtion of arrhythmias (I l,l2) and improvcmcnt in left 
ventricular function (14) that have been obscrvcd in some 
models. Although ischemic preconditioning has consistently 
been shown to reduce myocardial necrosis, its ability to reduce 
the frequency and severity of ventricular arrhythmias (3.4,13) 
and to improve left ventricular function (14,15) has not always 
been consistent. 
The biology of preconditioning has been characterized by 
several features: I) It is associated with a slowed rate of loss of 
adenosine triphosphatc (16). 2) It is not depcndcnt on an 
increase in collateral flow (3,s). In the initial studies of Murry 
ct al. (3) and in our own canine studies (S), an aculc rccruit- 
mcnt of collateral flow that could explain preconditioning was 
not observed, Furthermore, preconditioning has hcen shown lo 
work in animal models with little or no collateral flow, such as 
the rat, rabbit and pig heart (Fig. 1) (6-10). 3) Even a single, 
brief coronary occlusion preceding a longer period of ischcmia 
can precondition the heart. In the canine model, a brief, single 
occlusiolr for a period of only 90 s to 2.5 min appears Capable 
of preconditioning the heart (15,17,18). 4) The protcctivc 
effect of preconditioning can be lost when the duration of 
sustained ischemia is increased beyond 90 min to 3 h in animal 
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Table 1. Potential Mechanisms of Preconditionine 
Preconditioned 
Rabbits RtltS 
Flgnrc 1. EfFect of prcconditianing ischemia on infarct size in three 
species. Percent of lhe area at risk (AN/AR%) that developed necrosis 
in dogs subjected to ho min ofwronq occlusion alone (qca lw) or 
preceded byb&f periods of preconditioning ischemia (bat&d bar, 
rcf 5); in rabbits subjected to 40 min of occlusion followed by 
reprfusion (w bar) or preceded by preconditioning ischcmia 
(UC&I bar, rcf 7): and in rats subjected to W min of occlusion 
f&wcd by reperfusion (-II bar) or preceded by preconditioning 
iticmia (hat&d bar, ref 8). *Significantly different from control. 
models (4,5,19] orif there is a lengthy delay between the initial 
prmnditioning ischemic episodes and the sustained coronary 
occlusion (lS,ZO); however, as discussed later, investigators 
(21) have now described a second window of protection that 
reemerges 24 h after the initial ischemic preconditioning 
episode. Thus, protection occurs hortly after the initial pre- 
conditioning ischemia, fades after several hours and then 
reemerges a day later. 5) Tolerance to preconditioning may 
occur. In one study (22), frequent ischemic events for many 
hours resutted in a loss of precanditioning efficacy, at least in 
the rabbit model. 6) Sweral other forms of stress, when 
applied before a long period of ischemia, result in a precon- 
ditioning-like effect. These include hypoxia (23), stretch (24), 
heat shock (Zs), and alpha,adrenergic stimulation (X1,27). 
Mechanism of Ischemic Preconditioning 
Although the exact mechanism of ischemic preconditioning 
is still under investigation, several obvious theories have been 
eliminated. Ischemic preconditioning is not due to acute 
recruitment of collateral flow, stunning, acute synthesis of a 
protective protein, inhibition of mitochondrial denosine 
triphosphatase, paradoxic protection by oxygen .-adicals or 
enhanced production of antioxidants (28). Current favored 
hypotheses include the activation by adenosine (which is 
released during ischcmialreperfusion) of adenosine A, recep- 
tor, which couples to a G protein and through second- 
messenger pathways causes the translocation of protein kinase 






Activation of adeaosine r cq!ors* + activalion wf G prolehl + 
a&&n OF phqholipasc C 3 degradalian uf msmbranc phospholipids 
to d&ylglywml + activation or prolein kinase C + phosphorylation of 
unknmwn effector (6,29-31.35) 
Opening OF KnW channel (may be the unknown eiTeeaor in theory [IQ]) 
Stowing of&culysis with kss ilcidosis (33) 
Shess, hwt shmzk protein-may be impnanr for the semnd window of 
protection but not Br acute preconditioning (21,25,M) 
AIpha symplhctic stimulalbn (w&s through G protein as in theory 1 
PU71) 
*Holds true in rabbit modeIs but may IIDI occur in ral model of precondi- 
lion@. KA.,p = ahnosine Gphcqhare (ATP)-dependen potassium channel. 
unidentified protein that mediates protection (6,29-31). This 
protein may be the adenosine triphosphatedependcnt potas- 
sium channel, which becomes activated during preconditioning 
ischemia and results in a shorter action potentiai duration and 
a decrease incalcium influx, with a loss of contractile function 
and an enerwsparing effect (32). A reduction in glycnlysis 
with reduced intracelIular cidosis another potential mech- 
anism (33). Determining the mechanism of preconditioning s 
important because it may allow development of precondition- 
ing-like therapies for a wide range of cardiovascular disorders. 
Mechanisms of preconditioning are summarized in Table 1. 
Does Preconditioning Occur in Humans? 
Because preconditioning has been recognized asone of the 
mast powerful and reproducibie meth& of delaying cell 
necrosis known to date, the important question remains as to 
whether ischemic preconditioning can occur in humans. The 
clinical observation f preconditioning would have important 
therapeutic implications because once the mechanism of pre- 
conditioning is elucidated, it may form the basis for new 
therapies incardiovascular medicine. 
In the following sections we discuss those clinical situations 
in which preconditioning may occur and e&&e those situa- 
tions in which it has the potential to form the basis of therapy. 
At least fotir types of published studies upport the concept 
that preconditioning occurs in humans: 1) angioplasty studies 
that show lass ST segment shift and lactate production i  a 
subsequent, compared with a first, coronary artery balloon 
inflation; 2) clinical studies that suggest that angina preceding 
myocardial infarction confers acute beneficial effects; 3) stud- 
ies showing that acute tolerance to angina can develop; and 
4) studies that have directly examined hEman tissue specimens 
taken at operation in which biochemical and functional prop- 
ertiesof the tissue reWect a preconditioned state. The following 
sections review evidence from all four types of studied. 
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Angioplasty provides a unique opportunity ta study the 
response of the human hear! when exposed to brief periods of 
ischemia folIowed by repetiion; by definition it could be 
argued that balloon angiopfasty may indeed k a form of 
precondieioning. Deutsch et al. (36) provided some of the first 
evidence that preconditioning might occur in humans during 
repetitive angioplasty balloon inflations. They observed the 
intensity of angina, the degree of ST segment deviation 
(assessed from surface electrocardiograms [ECGsJ), the 
amount of lactate production and the mean pulmonary artery 
pressure during two sequential 90-s batloon inflations in 12 
patients. The second balloon-induced coronary artery occlu- 
sion was associated with less angina1 pain, less ST segment 
deviatjon (0,21 2 0.07 v5. 0.44 z 0.13 mV, p = O.Olj, less 
lactate production and a lower mean pulmonary artery pres- 
sure. Cardiac vein flow was slso lower during the second 
inflation than during the first, suggesting that the adaptation to 
ischemia was not due to an increase in coronary collateral 
bid flow. The lessened ischemic response during the second 
inflation supports the concept that the myocardium had been 
preconditioned by the first inflation. 
Tomai et al. (37) recently reported results in 48 patients 
who received either twc~ angioplasty balloon Mations for 
2 min using the same balloon inflation pressures or two 
inflations using a higher pressure during the second compared 
with the first occlusion. Both groups of parienes had less ST 
segr;lent shift during the second than in the first ballmn 
inflation, thereby confirming the initial findings of Deutsch et 
al. (36). The finding that angina1 pain was also less severe 
during the second Mation in patients whose Moon inflations 
were of equal pressure also agreed with the findings of Deutsch 
et al. However, patients whose second balloon inflation was 
performed athigher pressure actually had more severe angina 
during the second coronary occlusion even though they had 
less Si’ segment shift. The increased angina1 pain was thought 
to be related to the degree of stretching of the coronary artery 
wall. Unfortunately, coronary collateral blood flow was not 
measured in this study. 
Taggart et al. (338) recently reported results in seven patients 
who underwent augioplasty of the left anterior descending cora- 
nary artery with two 90-s balloon inflations separated by2 min of 
reflow, The degree of ST segment elevation measured with an 
epicardial electrogram from the angioplasty catheter guide wire 
wti sigrtificantly ess during the second than during the first 
balloon inflation. In addition, the action potential duration was 
also less during the second inflation, The investigators conduded 
that their findings upported the concept hat the human heart 
could be preconditioned and that he decrease in action potential 
duration on the gcond inflation wx consisten: with the view that 
adertosine triphosphatesensitive @aGum channels (which are 
known to shorten action potential duration) may have been 
ZVXiKlted. 
Cribier et al, (39) studied 17 patients with stenosis of the 
left anterior descending coronary artery. Patients underwent 
five successive balloon iniiations for a mean of231 s (range l:O 
to 370), with an interval of 3 to 5 min between i flations, TIk 
severity ofangin% degree of STsegment elevation (md ti 
both surface and Zntracoronary EC&), elevation of left ven- 
tricular end-diastolic pressure and deterioration in ejcxti~ 
fraction were less during IIXZ last two bakon inflations than $S 
the early inflations. Howaer, in tkir study, co~ry cc&e@ 
angiographic grade increased in 10 patients but remained the 
same in 7. Thus, in some patients, the improvements obsew 
with subsequent balloon i&ions may have been due to EUI 
acute recruitment of coronary collateral channels rather th&J 
to preconditioning. In animal studies preconditionjng is IIO~ 
due to an acute increa~ in collateral ftow; indeed, it has been 
described in auimals with minim&l to nu native coronary 
co!lateral circulation (stich as the pig and rat). Thus, it is those 
patients who experienced l ss evere angina nd ECG changes 
during later balloon inflations, withcut an acute recruitment of 
collateral channek, who may have had true preconditiq 
with the first brief inflation. 
The relations among angioplasty, opening of collateral 
channels and ischemic preconditioning are difficult to recon- 
tile. For example, Heibig et al. (40) described a patient who 
demonstrated angina and ST segment changes during a first 
balloon inflation but not in s&sequent inflations. However, 
distal coronary occlusion pressure progressively increased ur- 
ing subsequent balloon inflations >2 min in duration, suggest- 
ing that in this patient, acute recruitment of coronary collateral 
flow was contributing to the benefit. 
The duration of balloon inflation may be an important 
determinant of whether preconditioning occurs in humans. If 
the duration is ~1 min, preconditioning apparently does nut 
occur (41-431, The ischemic time r quired to precondition the 
: Iyocardium has been well characterized in the animal Mom- 
tory and is on the order of a minimum of 2 min or a maximum 
of 15 min of iahemia (44). 
Not all angioplasty studies have suggested an adaptive 
phenomenon between the first and subsequent balloon infla- 
tions. Denys et al. (45) observed no difference in the maximal 
ST segment elevation between a first and second bakxuI 
inflation. Although the time to maximal ST segment ekvation 
increased with a second inflation in some patients, Denys et al. 
attributed this increase to “preinflation ischemia from de- 
creased blood flow dur: to obstruction from the uninflated 
balloon across the lesion,” that occurred before full inflation 
during the first occlusion, DeBruyne t al. (46) reported Iess 
angina fter a fourth 15&s angioplasty than after a first baIIoon 
inflation. This decrease was not atiated with an increase in 
coronary wcdgc pressure, suggesting that collateral channels 
had not been recruited by the first balloon inktion. However, 
the investigators did not ckerve any difference inleft ventric- 
ular function between the two occlusions and concluded that 
angioplasty was not a good model of preconditioning, In viva 
animal studies (IS) have failed to demonstrate any acute 
benefit of preconditioning o  rcgionaf left ventricular function 
of stunned myocardium. 
In conclusion, xveral angioplasty udies have documented 
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less a@nu and ST segment change on a subsequent than on an 
initial ballmn inflation. In some of these studies, the benefits 
were not associated with acute recruitment of coronary CO!!at- 
eral flow and thus may represent true preconditioning of the 
e patients, however, the beneficial effects 
nt balloon inflations appeared to be due 
of collateral channels: in these cases true 
preconditicning mzy not be the mechanism of the beneficial 
e#ect. Nevertheless, even these cases suggest that the heart has 
the ability to acutely invoke endogenous protective mecha- 
nisma 
It ki not uncorn~~t~~~ for paticrrts to cxpericncc brief cpi- 
an acute myoccardial inbrctisa. Thcsc 
form of angina or silent myocardial 
th. It coutd be argued that preinfarction 
the potential to precondition the 
ticnts with a history ot angina preceding 
my-ocardial infarction are more likely to have multivesscl 
coronary artery disease (48) and, in some studies, a worse 
long-term prognosis (49). If preinfarction angina preconditions 
the heart, it may confer only transient immediate protection at 
the time of infarction, rather than fang-term protection. he- 
ewe of the likely occurrcncc of additional coronary cvcnts in 
paticnls with muitivcssci coronirq ;rrtcry discasc. IR iuir!ition. if 
prcinfarction angina wcrc to precondition the heart, one would 
predict that it would do so only in infarcts that had been 
rcpcrfuscd. bccausc cxpcrimcntal studies (3,530) hitvc shown 
that preconditioning rcduccs myocardiai nfarct size only when 
reperfusion is induced in a timely fashion. In analyzing puh- 
lished data on pninfarction angina, it is important to deter- 
mine which end points of myocardial infurction arc being 
In cxperimentsl studies, the end point that has most 
tiy benetitcd from ischemic preconditioning is a rc- 
duction in inhrct site (1); other end points thaa have shown 
b+zrtefiI from ischemic preconditioning in at least some models 
and species include improved left ventricular function (primar- 
i!y in studii of global left ventricular function) and reduction 
in arrhythmias (I l,l2), Finally, some asscssmcnt of coronary 
dateral flow is useful for determining whether heneficiai 
effects are truly due to preconditioning or simply the result of 
development or recruitment of new collateral channels. 
With these mncepts in mind, the following section reviews 
rts on the effects of previous angina on outcome of 
nfnrction. Although several of these studies ltavc 
reported beneficial effects of previous angina, others have 
~p‘td deleterious effects; both types of studies are discussed 
here. Or@ a few studies have reported angina tempor;~tIy 
&WI to the myocardial infarction. Nevertheless, patients 
with a history of angina probably have a greater likelihood of 
having brief periods of ischemia or silent ischemia before 
infarction than do patients without a history of angina. 
Studies showing positive effects of previous angina on 
myacardial infarction. Cortina et at. (48) observed that pa- 
tients with a history of angina for at least 1 month before 
myocardial infarction were more likely to have multivessel 
coronary artery disease and a higher coronary collateral score. 
These patients had better postinfarction global and regional 
left ventricular function than did patients without a history of 
previous angina. Preservation of left ventricular function after 
anterior wal! infarction in patients with a histoq of previous 
angina was rclatcd not only to more collateral vessel develop- 
mcnt, but also to a more distal obstruction of the left anterior 
dcsccnding coron:~ry artcv’. Patients with inferior wa 
dial infarction and previous ililgitla also had hcttcr 
tion of regional f~lncli~}l~. Hawcvcr. most patients wi 
wall infarction (with or without previous angina) had well 
formed coilatcral vcsscls, tending the irvcsti@ors to conclude 
that “smalicr infxcts” in thcsc patients m;iy bc tmrclatcd to 
the prcscncc or degree of visible c~~il~tcr~l vessels. Thus, 
although coliatera! channels may have piaycd ;I bcneficis! 
effect in p&!nts with anterior my(lci~rd~~~! infarction, they 
could not CXQhin the !renefit IIf ~rcyio~s angina in those with 
inferior infarction. it is couccivablc that prcc(~nditi~~nitlg may 
have p!ayed a rote. 
~~tsud~~ et al. (51) reported the effect of preccdi~g ~~~gi~il 
(defined as angina for >7 days before the onset of acute 
myocardial infarctinu) ofi !eft vel~~~icM~~~ function in 31 Qa- 
tients who had acute myt~ardial infarction due to total occlu- 
Gon of the left anterior dcsccnding coronary artcry. In thcsc 
patients with a history of previous angimi. the mean cjcction 
fraction was d”F? c~~~i~lred with 3% in those without imgina. 
The pcrccnt of ahnormally contracting segments on icft vcn- 
triculirr iitlgi0grapily was 21% in patients with versus 34% in 
those without previous angina. In contrast to the study of 
Cortina ct al. (48). patients with a history of previous angina 
did not have better developed collateral channels than those of 
patients without angina. The invcstig~~t(~rs concIuded that a 
history of angina preceding myocardial infarction “could be a 
favorahlc sign in preserving [left vcntricularl function when the 
patients had myocardial infarction.” 
Whereas Matsuda et al. (Sl) did not observe more coilat- 
eral channels in patients with previous angina, Fujita et al, (52) 
described more visihic collateral vessels in their patients, Hirai 
ct al. (53) also dcscrihcd more coliatcral vessels in patients who 
cxhihitcd angina for >I week before infarction, and they 
ohserved better regional wall motion and a higher global 
ejection fraction (S4% vs. 35%) in those patients than in 
patients without angina. Patients with preinfarction angina 
occurring only during the I week hcfore infarction had neither 
improved collateral flow nor improved left ventricular ejection 
fraction. 
Muller et al. for the Thromholysis and Angiopiasty in 
Myocardiai Infarction (TAMI) study group (54) studied the 
effect of a history of angina in 775 patients with acute 
myocardial infarction. In that study, previous angina was 
defined as recurrent pain beginning >7 days before the 
infarction; patients received reperfusion therapy with either 
t~~r~~~~b~~lyti~ agents or per~ut~~~~~~~~s tr~~~~s~~~~i~~~l coronary 
atients with chronic dngina ha 
ptdernia and diabetes. Similar to 
tients with 
~sel coro- 
nary artery disease (5W vs. -We, p < O.OOO!); in addition, 
scline left ventricular ejection fraction. 
ad a lower rate of reocclusion of the 
(8% vs. 14%. p < 0.05) and a trend 
ward a lower in-hospital mortality rate (4.6% vs. 7.2%). 
owever, despite this trend to fewer in-hospital deaths, the 
cumulative I-year survival rate (SC)%) was similar to that of 
ut prec~~di~l~ ~~~~gitl~~ (YOR ). Measures of coro- 
11 llow were not provided. Among the possible 
~~i~~i~lli~~~~~l~s fW Ihe better Sl~(~~t~t~~l~~ WtCOiW in patients with 
previous Mgillil, lhe investigators included prc”“i”ditionillg. 
~l~h~I~~e(~ collateral perfu~i~ or previous therapy with beta- 
blockers or calciulll clxlnncl blockers. 
ilIly Of 1hC previously dihcusscd studies focused csclusivcly 
on the prcsensc or abscncc of previous chmic ;rngim. A thJ 
preliminary reports have described angina occurring tempo- 
rally close to the infarction. Ottani et al. (55) studied 13 
patients with angina occurring within 24 h of illlkri0~ myocar- 
dial infarction and I3 patients who did not experience angina: 
all patients received thrombolytic therapy. Angiography 
showed no cvidcnce of collateral Ao\~~. Infarct size assessed by 
peak creatine kinasc (CK), MB fraction was lower in patients 
with than in tlmsc without previous angina (6Y vs. 210 Uilitcr). 
In addition the number of hypokinctic segments \vits also 
smaller in the angina group. 
Kloncr et ;11. (56). in it pr~li~ni~i~i~~ report based on data 
obtained from the Thrombolysis in Myocardial Infarction 
(TIMI)- study, noted that patients with angina within 38 h of 
myocardial infarction or with any history of previous angina 
had a lower in-hospital death rate, a lesser frequency of scvcrc 
congestive heart failure and shock and ;I smaller infarct size 
assessed by CK curve analysis. There was no dilferencr in 
visible epicardial coronary collateral vessels assessed on the 
YO-min coronary angiogram between patients with and without 
angina. In addition, the beneficial effects did not appear to 
depend on the use of antianginal agents or aspirin. In this 
study, the time to thrombolytic therapy after the onset of pain 
was longer in the patients with preexisting angina (presumably 
because in such patients it may not initially be clear whether 
the pain is an angina1 episode or a myocardial infarction). The 
investigators concluded that one potential mechanism for the 
postinfarction benefits in these patients was ischemic precon- 
ditioning. However, despite these early benefits, there was a 
trend for patients with a history of angina to report more 
recurrent chest pain. 
Thus, several studies have suggested that previous angina 
may have an acute benefit in patients with myocardial infarc- 
tion, In summary, two studies (5556) have demonstrated a 
reduction in infarct size, independent of large epicardial 
collaterai vessels. Four studies showed a benelit on left ven- 
tricular function; in two studies (4853) this benefit was related 
at least in part to better collateral perfusion in the angina 
C rern~~i~i~~g two studies (5P,j5), the improvement 
in function was not mediated by t e presence of visible 
collateral vessels. Two studies (5456) ISO showed a trend for 
patients with previous angin- u to have a lower in-hospital 
mortality rate. In one study this trend was independent of 
collateral vessels (56); in the other (54), collateral data were 
not presented. These investigations support the concept that 
the heart may be able to adapt to ischemia before a myocardial 
~iifar~tio~. In some studies the adaptation “nay have been 
direct preconditioning. In other studies, in which an increase in 
collateral vessels occurred, the mechanism is unlikely to have 
been true preconditioning which, as described in the animal 
studies, is not dependent on an increase in collateral channels. 
is conceivable that both mechanisms-an increase in 
VCSSC~S d pr~cl~l~dit~ol~ing~oc~~r in some pa- 
em. 
lies have shown that for ischcmic precondi- 
tioning to be cffcctive, the myocardial infarct must be reper- 
fused in a timely fashion. In other words, there is a limit to the 
duration of prolonged ischemia that can be protected by 
previous episodes of brief ischemia. In the canine model, 
preconditioning appears to lose its protective effects once the 
duration of prolonged ischemia extends beyond 60 to 90 min 
(2.3,S,lY.26.33.50). Thus, without rcperfusion, one would not 
cxpcct previous angina to have a protective effect: in fact, a 
rcvicw of published studies from the prctllromholytic era 
wper ct al. (57j rcportcd data from 577 patients with 
ilcutc myocsrdial infrtrction between lY6Y and 1075: 3tll 
piltiUltS (52%) had a history of angina in the month before 
myc!ew!ia! in?hrcth!~ whereas 75% of these patients had 
unstable angina. Patients with no change in the pattern of 
angina before infarctton (n = 75) had a nonsignificant trend 
toward a higher hospital mortality rate (20%) than that of 
patients with no angina (120/o), chronic stable angina with an 
increase in severity (14%) or angina of new onset (12%). 
Marcover, patients with a history of chronic angina before 
infarction tended to have a non-0 wave infarction. 
Cupplcs et al. (49) reported long-term (up to 34 years) 
prognosis of patients in the Framingham trial who had preex- 
isting angina before myocardial infarction. Of 828 patients with 
acute myocardial infarction, 21% of men and 25% of women 
had preceding angina pectoris. Men and women with previous 
angina were more likely to die of coronary heart disease over 
the ensuing 30years. As mentioned earlier, the likelihood that 
patients with previous angina have more multivessel coronary 
artery disease may account for the Framingham observation. 
Kloner et al. (unpublished observations) recently analyzed 
the results of another prethrombolytic trial, the Multicentcr 
Investigation of the Limitation of Infarct Size (MILIS) study. 
Patients with previous angina were more likely to have recur- 
rent ischemia, mitral regurgitation and infarct extension, with 
no evidence of smaller infarct size. Negative effects Of previous 
1138 KLONER AND YELLON 
ISCHEMIC PRECONDITIONING IN HUMANS 
JACC Vol. 24. No. 4 
October 199&l m-42 
angina were observed in patients with both angina within 3 
weeks of infarction and a history of angina >3 weeks before 
infarction. 
s&jes from the thrombolytic era. Several studies per- 
formed in the thromboiytic era have concluded that a history of 
an&a before myocardiai nfarction results in a worse iong- 
term outcome. For example, Pierard et al. (58) described data 
from 732 consecutive patients admitted with a first myocardiai 
infarction. Two hundred eighty-five patients (39%) never had 
angina before infarction; 200 (27%) had chronic angina for a 
minimum of 1 month before infarction, whereas 247 patients 
(34%) had angina of new onset within 1 month of infarction. 
ina tended to be older and female and to have 
farction angina nd anterior infarction. In- 
hospital mortality was imilar between patients with (10%) and 
without (8%‘ p = NS) previous angina. However, the 3-year 
posthospital mortality rate was greater in patients with (16%) 
than in those without (7%, p e 0,001) angina before infarction. 
There were no differences in clinical outcome between patients 
w&h chronic versus new onset angina. 
Similarly, Ruocco et al. (59) reported in the TIMI II study 
that a history of angina before infarction was associated with 
more recurrent in-hospital chest pain (32% vs. 22% in patients 
without angina) and a higher likelihood of recurrent infarction 
during the first year after infarction (11% vs. 8%, p = 0.001). 
As expected, previous angina was associated with more mtil- 
tivessel disease. However, these patients had greater residual 
narrowing of the infarct-related v ssel after thromboiysis (77% 
vs. 73%, p < 0,001). The finding of Ruocco et al. (59) of more 
in-hospital recurrent ischemia and muitivessei disease was in 
agreement with data from the recent TIM1 4 study (56). 
However, unlike the TIMI 4 ijudy, there were important 
baseline differences between patients with and uithout previ- 
ous angina that might have xpiaincd the deleterious outcome, 
Patients with previous angina in the TIM1 II trial were more 
likely to be older, have anterior infarction, and have a history 
of heart failure, hypertension, diabetes and smoking. Although 
us angina were sicker on hospital admis- 
(59) observed that he early mortality rate 
nd without antecedent angina was low and 
not significantly different (4.9% and 4.0%, respectively). 
Barbash et al. (60) presented data from the International 
Tissue Plasminogen Activatorfitreptokinase Mortality Trial. 
Before acute myocardiai infarction, 4 447 patients reported no 
angina, 2,370 patients had previous angina for >1 month, and 
1,512 patients reported angina for ~1 month. In contrast tothe 
TIMI 4 study, patients with or without angina differed at 
b Patients with angina had a higher incidence of 
h sion, diabetes, hyperchoiesteroicmia, s oking and a 
poorer Fillip classification. Moreover, incontrast to the TIM1 
trial& PEWiOuS angina was associated with higher in-hospital 
mortality (18% vs. 12% in those without angina). The investi- 
gators reported that preceding angina was associated with a 
higher 6-month mortality rate, a greater incidence of early and 
late reinfarction, a greater incidence ofcoronary artery bypass 
surgery and a higher Kiilip class on hospital discharge. They 
noted that the worse clinical outcome may have been due to 
the higher frequency ofmultivessel disease known to occur in 
such patients. Similar esults were reported by Behar et al. 
(61), who also found that baseline characteristics differed 
between patients with or without angina nd that previous 
angina was more commonly associated with non-Q wave 
myocardiai nfarction. 
In summnry, studies that have assessed the outcome of 
patients with angina before myocardial infarction have in,
general, showed aworse long-term prognosis, presumably as a 
result of more multivessel coronav artery disease. Differences 
in baseline characteristics, such as age3 presence ofhyperten- 
sion, smoking and heart failure on admission, may also have 
contributed to worse long-term outcome. 
of previous angina on short,,term in-hospital outcome r mains 
debatable. Some studies (54~56) reported beneficial effects of 
previous angina, including smaller infarct size and a trend 
toward fewer in-hospital deaths, which may be xplained at 
least in part by preconditioning. In contrast, other studies 
(60,61) showed that previous angina dversciy affected even 
short-term hospital outcome, and still others (62) showed a
neutral effect. The reason for the discrepancy among these 
studies is not known, but it could include differences in
baseline characteristics and in the num er and timing of 
ischemic episodes before myocardial nfarction. 
Adaptation to Angina 
Two reported phenomena-“walk-through” angina and 
-may represent a clinical counter- 
part o preconditioning. The “walk-through” angina phenom- 
cnon was described as early as the late 1700s (63) in a patient 
who developed angina with exertion but experienced the 
paradoxic disappearance of angina as exercise continued. 
Wumz-~r~p~~cno~ne~~o~~ refers to the situation i  which a patient 
stops exercise because of angina but then is able to resume 
exercise without developing further angina. Both phenomena 
have been documented with exercise stress testing (64). Jaffe 
and Quinn (65) studied 34 patients who underwent an initial 
exercise t st, followed by 30 min of walking, 20 min of rest and 
then a second exercise t st. There was less KG evidence of
ischemia (less ST segment deviation) on the second than on 
the first test, even though rate-pressure product at peak 
exercise was higher during ihe second test. Okazaki et al. (66) 
studied 13 patients with angina nd compared the results of 
two consecutive exercise t sts performed 15 min apart in the 
catheterization laboratory. Patients exercised longer before the 
development of angina during the second test (507 s) than 
during the first est (410 s) and also developed less SIT segment 
depression during the second (1.1 L U.2 mm) than during the 
tirst (1.7 ? 0.2 mm) test. Although emodynamic variables and 
flow through the great cardiac vein did not differ between the 
two tests, regional myocardial oxygen consumption was lower 
during the second test. One extremely interesting observation 
was that adenosine r lease into the great cardiac vein was 
greater during the second test (3.9 vs. 2.5 nmoi/min, p < 
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.01). The investigators conclu 
enon was due not to an increase in collateral 
reduction in myocardi 
ated by adenosine A 
regard to the warm-up 
al. (67), who induced with two identical 
pacing-induced tacbycardia separated by a 5- to 15-min recov- 
ery period. Severity of angina and degree of ST segment 
depression were less daring the second than during the first 
episode of pacing, and lactate extraction decreased less during 
the second pacing period. Similar to findings in the previous 
study, peak coronary blood flow during the second episode of 
pacing did not differ from that during the first, whereas 
regional myocardial oxygen consumption decreased dMri~~~ the 
second pacing period. 
TIllIS, tlltX studies (64-07) SU&J_!St tklt piltiClltS till1 
develop sudden t&~mcc to imgiua induced by exercise- or 
pacing-induced tachycardia. In at least two studies (60,67) this 
tolerance appeared to bc related not to an increase in collat- 
era6 110~ but to 21 d t&on in rcgiomd ~lyocard~il6 oxygen 
consumption. Certainly, one potCIltiid explanation for these 
observations is preconditioning, and the observation that aden- 
osine release was greater during a second episode of ischemia 
than during the first fits in closely with the observation that 
adenosine receptors seem to be activated during precondition- 
ing in some of the animal models. A recent review (68) of the 
relation of warm-up in angina and preconditioning has been 
published. 
Studies Exantinitzg Precondiriorhg in 
Myocardial Samples 
If the human heart can bc preconditioned, then human 
myocardium should demonstrate the biochemical “signatures” 
of preconditioning as elucidated in the experimental labora- 
tory. One such hallmark study is the slower rate of adenosine 
triphosphate depletion after episodes of preconditioning, as 
shown by Murry et al. (66) in the canine model. In this regard, 
Yellon et al. (69) examined human myocardial biopsy speci- 
mens obtained at the time of coronary artery bypass surgery. 
Fourteen patients were randomized into two groups. One 
group underwent a specific preconditioning protocol consisting 
of two 3-min episodes of aortic cross-clamping with 2 min of 
reperfusion between each episode; this was followed by the 
period of “sustained ischemia” consisting of 10 min of aortic 
cross-clamping while the heart was electrically fibrillated and 
distal aortocoronary anastomoses were performed. Control 
patients did not undergo intermittent aortic cross-clzmping 
before the IO-min test period of ischemia. At the end of the 
repeated brief ischemic episodes, adenosine triphosphate lev- 
els were, as expected, lower in “preconditioned” patients than 
in control subjects. However, during the test ischemia, adeno- 
sine triphosphate decreased in the control group (born 19.8 to 
6.8 pmol/g dry weight); there was no decrease in adenosine 
triphosphate during this time in those patients who had 
received a preconditioning protocol with intermittent aortic 
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le 2. Clinical Evidence Supporting the 
Angioplasty studies that shuw less ST segment shift. chest pain and lactate 
production on a second than on ;I first balloon inflstion 
Clinical studies showing that preinfarction angina reduces infarct size and 
impr ws outcome (especially in those sludies showing no increase in 
collateral flow) 
Acute tolerance to angina: “warm-up” phenomenon and “walk-through 
angina” 
Preservation of adenosine triphosphate with intermittent aortic cross- 
clamping. In vitro studies on isolated human cardiac muscle and isolated 
cardiac nvyxytes showing preservation of ftinction and viability when 
preconditioned 
cross-clamping (from IO.5 to 12.0 pmol/g dry weight). This 
study was the first to demonstrate that human myocardial 
tissue could show biochemical hallmarks of preconditioning. 
Walker et al. (70) recently studied human right atria6 
trabeculae suspended in an organ bath to ascertain whether 
such muscle could be preconditioned. One group of muscles 
was preconditioned with 3 min of rapid pacing at 3 Hz during 
superfusion with hypoxic, substrate-free buffer, followed by 
reoxygenation with substrate for IO min and pacing at I Hz. A 
second group received no intervention. Both groups were then 
subjected to a test period of ischemia consisting of rapid pacing 
at 3 Hz for 90 min during superfusion with hypoxic substratc- 
free buffer, followed by 120 min of reoxygenation and pacing at 
I Hz. The percent recovcly of developed tension at 120 min of 
reoxyenation was greater in the preconditioned group than in 
the control group (49% vs. 23% p = 0.0001). These investi- 
gators also demonstrated that such human muscle could be 
preconditioned pharmacologically with the use of the adeno- 
sine A, agonist R-PIA. The pharmacology of such agents has 
been suggested to be at the center of the mechanism through 
which such protection by preconditioning is manifest (6). 
lkonomidis et al. (71) similarly demonstrated that isolated 
human cardiomyocytes could be preconditioned. Human ven- 
tricular myocytes were obtained at the time of cardiac surgery 
and grown in culture. Cells were exposed to anoxia for 90 min, 
followed by exposure to normoxia for 30 min. Preconditioning 
the cells with 20 min of anoxia followed by 20 min of 
reoxygenation reduced cell injury to the subsequent longer 
90 min of ischemia: Specifically preconditioned cells had ICSS 
uptake of trypan blue and increased survival. Moreover, the 
supernatant from preconditioned cells had a lower hydrogen 
ion, lactate and lactic dehydrogenase concentration. The in- 
vestigators concluded nor only that human myocardial cells 
could be preconditioned, but that this preconditioning OC- 
curred independently of interactions of other cell types. 
Therefore, several lines of evidence now suggest that hu- 
man myocardial tissue can indeed be preconditioned (Table 2). 
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Potential Therapeutic Ap 
of Preconditioning 
mere arc several potential therapeutic applications of 
preconditioning to clinical medicine. Yellon et al. (69) raised 
the possibility that intermittent aortic cross-clamping might 
confer protection to hearts while patients are on cardiopulmo- 
nary bypass. The same concept could be applied to donor 
hearts removed for transplantation: These hearts might have 
better preservation during transportation if they are subjected 
to brief periods of ischcmia before transportation. 
An arca of extremely active research over the past 5 years in 
numerous experimental laboratories has been the search 
for the mechanism of preconditioning, which may lead to 
preconditioninglike thcrapcutic intcrvcntion. Current popular 
concepts include stimulation of one or more types of rcccptors, 
such as adcnosinc A, (6) or A, (35) receptors, muscarinic 
receptors or alpha sympnthomimotic rcccptors (72), which, 
through G proteins, (29) result in the translocntion of protein 
kinase C to the cell mcmbranc and subscqucnt phosphoryla- 
tion of an as yet unknown etfcctor (31) such as the adenosinc 
triphosphate-dependent potassium channels (32). 
Moreover, Marber and colleagues (21) recently described a 
“second window of preconditioning” that is manifest late 
(~24 h) after the initial preconditioning episodes and may 
involve some form of molecular adaptation, stimulating the 
production of heat shock protein, Evidence for this second 
window of protection also comes from Kuzuya et al. (34). who 
demonstrated the same phenomenon in dogs 24 h after short 
episodes of preconditioning &hernia. Most recently, this late 
preconditioning ellect was suggested by Baxter ct al. (73) to 
occur through an udenosinc-octivatcd protein kinasc C mcch- 
nnism. If this second window proves to ho a real phenomenon 
rcprcsenting it Iatc ischcmic adaptation, it could have impor- 
tant clinical implications. For example, an ischemic cvcnt such 
IS angina on one day might protect a patient agains! further 
i>schomic injury on the next day. 
Therefore, tis the mechanism or mechanisms of both early 
and late preconditioning are elucidated, “prcconditioning- 
mimetic” agents might be administered prophylactically in 
certain situations-for example, before coronary artery bypass 
surgery or before removal of the heart for transplantation-or 
possibly in high risk patients with angina. In this regard, one 
adenosine triphosphate-dependent potassium channel 
opener, nicorandil, is already used in some countries in 
patients with angina. Adenosinc and adenosine agonists have 
been shown to mimic preconditioning in rabbit models of 
myocardial infarction (6). but their potential clinical role is not 
clear: At least one preliminary study (74) in which adenosinc 
was administered along with thrombolytic therapy for acute 
myocardial infarction failed to show a benefit. Agents that 
initiate the translocation of protein kinase C from the cytosol 
to the cell membrane (31) may in theory also provide a 
potential therapeutic approach. Trandocation of protein ki- 
nase C by phorbol myristate acetate does, in fact, protect 
isolated rabbit hearts from sustained global ischemia, but these 
agents are toxic in in vivo preparations. Finally, other agents, 
such as muscarinic agonists (29,75) and sympathomimetic 
alpha, receptor agonists (norepinephrine, phenylephrine), can 
also mimic preconditioning (26,27,35). However, in the setting 
of angina, sympathomimetic agents, by increasing blood pres- 
sure, can increase oxygen demand and, by increasing coronary 
vascular resistance, can decrease oxygen supply and hence 
worsen ischemia. Therefore, the optimal “preconditioning- 
mimetic” agents remain to be found and, as Cohen and 
Downey (76) have rightly stated, “Putting preconditioning in a 
bottle remains a pharmacologic hallenge.” 
Another potential clinical ~~pplicati~~n of prec~)nditio~ing is 
the treatment of arrhythmias. Several experimental studies in 
the rat model have shown that ischcmic ~rec~~~ditionillg can 
reduce the frequency of ischemia- and ~epcrf~si(~~-il~duced 
ventricular arrhythmias (8,l l-13). If the mcclnmism of this 
antiarrhytbmic ctfect of preconditioning can bc detcrmincd. 
then it is possible that “prcconditicning-l~~il~lctic” drugs might 
cvcntually be developed to prcvcnt life-thrcatcning arrhyth- 
miss. 
lschemic preconditioning has been demonstrated to offer 
the myocardium the most powerful p~~~tecti~~n, other than 
rcperfusion, from ischemic necrosis. It reliably and consistently 
reduces myocardial infarct size. in a range of animal species. 
The big question, however, is. Does it occur in humans? We 
bclicvc that this review supplies early evidence supporting the 
concept that ~~l~li~n hearts adapt to iscbemia and that at least 
one aspect of this adaptation may involve preconditioning. 
Increased tolerance to repetitive balloon inllations during 
angioplasty has been observed by several investigators. Some 
but not all studies sugest that prcinfarction angina has an 
early beneficial elfect, but interpretation of these data arc 
confounded by the fact that angina preceding myocardial 
infarction is usually associated with more multivessel disease. 
Thus, although preinfarction angina might confer some early 
in-hospital benefit, it tends to be associated with more recur- 
rent ischemia and a worse longer term outcome, necessitating 
the riced for more interventional procedures. Nevertheless, 
prcinfarction angina was associated with smaller infarct size in 
at least two recent thrombolytic trials. 
Several studies suggest that patients develop acute toler- 
ance to repetitive episodes of exercise or pacing-induced 
ischemia, and this may also represent preconditioning. 
There is now convincing evidence that human myocardial 
tissue can be preconditioned. Both in vivo studies of intermit- 
tent aortic cross-clamping and in vitro studies of isolated 
trabecular muscle and isolated human ventricular myocytes 
have suggested that this tissue is protected by brief periods of 
ischemia. 
Finally, preconditioning or “preconditioning-mimetic” 
agents may, in the future, be applied therapeutically in in- 
stances of cardiopulmonary bypass, heart transplantation, an- 
gina and myocardial infarction. 
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